Search Results - "Choi, Hun Mi"

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer by Yun, Mi Ran, Kim, Dong Hwi, Kim, Seok-Young, Joo, Hyeong-Seok, Lee, You Won, Choi, Hun Mi, Park, Chae Won, Heo, Seong Gu, Kang, Han Na, Lee, Sung Sook, Schoenfeld, Adam J, Drilon, Alexander, Kang, Seok-Gu, Shim, Hyo Sup, Hong, Min Hee, Cui, J Jean, Kim, Hye Ryun, Cho, Byoung Chul

“…Although first-line crizotinib treatment leads to clinical benefit in lung cancer, high prevalence of crizotinib-resistant ROS1-G2032R (ROS1 ) mutation and…”
Get full text

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer by Yun, Mi Ran, Choi, Hun Mi, Lee, You Won, Joo, Hyeong Seok, Park, Chae Won, Choi, Jae Woo, Kim, Dong Hwi, Kang, Han Na, Pyo, Kyoung‐Ho, Shin, Eun Joo, Shim, Hyo Sup, Soo, Ross A, Yang, James Chih‐Hsin, Lee, Sung Sook, Chang, Hyun, Kim, Min Hwan, Hong, Min Hee, Kim, Hye Ryun, Cho, Byoung Chul

“…Clinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKIs) in ALK ‐rearranged lung cancer has been limited by the inevitable development of acquired…”
Get full text

Abstract 2054: Cerivastatin overcomes the acquired resistance to crizotinib in EML4-ALK positive non-small cell lung cancer by controlling YAP activation by Yun, Miran, Choi, Hun Mi, Pyo, Kyoung Ho, Cho, Byoung Chul

“…Crizotinib is highly effective in patients with non-small cell lung cancer (NSCLC) harboring the echinoderm microtubule-associated protein-like 4…”
Get full text

Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors by Yun, Mi Ran, Lim, Sun Min, Kim, Seon-Kyu, Choi, Hun Mi, Pyo, Kyoung-Ho, Kim, Seong Keun, Lee, Ji Min, Lee, You Won, Choi, Jae Woo, Kim, Hye Ryun, Hong, Min Hee, Haam, Keeok, Huh, Nanhyung, Kim, Jong-Hwan, Kim, Yong Sung, Shim, Hyo Sup, Soo, Ross Andrew, Shih, Jin-Yuan, Yang, James Chih-Hsin, Kim, Mirang, Cho, Byoung Chul

“…Anaplastic lymphoma kinase (ALK) inhibitors are highly effective in patients with fusion-positive lung cancer, but acquired resistance invariably emerges…”
Get full text

Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation by Kang, Han Na, Choi, Jae Woo, Shim, Hyo Sup, Kim, Jinna, Kim, Dae Joon, Lee, Chang Young, Hong, Min Hee, Park, Seong Yong, Park, A-Young, Shin, Eun Joo, Lee, Seo Yoon, Pyo, Kyoung-Ho, Yun, Mi Ran, Choi, Hun Mi, Lee, Sung Sook, Kim, Seok-Young, Lee, Hanna, Paik, Soonmyung, Cho, Byoung Chul, Lee, Jin Gu, Kim, Hye Ryun

“…•We established 41 NSCLC PDXs by directly implanting tumor specimens of patients.•These established PDXs were genetically and clinically annotated.•The…”
Get full text

Repotrectinib exhibits potent anti-tumor activity in treatment-naive and solvent-front-mutant ROS1-rearranged non-small cell lung cancer by Yun, Mi Ran, Kim, Dong Hwi, Kim, Seok-Young, Joo, Hyeong-Seok, Lee, You Won, Choi, Hun Mi, Park, Chae Won, Heo, Seong Gu, Kang, Han Na, Lee, Sung Sook, Schoenfeld, Adam J., Drilon, Alexander, Kang, Seok Gu, Shim, Hyo Sup, Hong, Min Hee, Cui, J. Jean, Kim, Hye Ryun, Cho, Byoung Chul

Get full text

Abstract 3835: High-purity patient-derived cells: An advanced cell culture model for precision cancer medicine by Kim, Seok-Young, Kim, Hwan, Kim, Sung-Moo, Kim, Hye Ryun, Yun, Mi Ran, Lee, Ji Min, Choi, Hun Mi, Cho, Byoung Chul

“…Purpose: Patient-derived cells (PDCs) established from malignant effusions can represent an excellent tool for the study of non-small cell lung cancer (NSCLC)…”
Get full text

Abstract LB544: Targeting adaptive metabolic program as a novel treatment approach for TKIs-failed ALK-positive NSCLCs by Lee, You Won, Choi, Hun Mi, Oh, Seung Yeon, Lee, Eun Ji, Pyo, Kyoung-Ho, Kim, Jae Hwan, Byeon, Youngseon, Heo, Seong Gu, Lim, Sun Min, Hong, Min Hee, Kim, Chang Gon, Kim, Hye Ryun, Yun, Mi Ran, Cho, Byoung Chul

“…Introduction: Acquired resistance to ALK-tyrosine kinase inhibitors (ALK-TKIs) treatment, particularly target-off resistance, remains a clinical challenge for…”
Get full text